ConductScience.org, home

Paper33552829

MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway.

Tang C and 8 others. 3 Biotech, 2021. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway. Papers, record 33552829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33552829

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway.
PubMed
Journal
3 Biotech
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.65
iCite
Revised in PubMed
2022-04-20
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tang CChaofeng
2Yuan PPeng
3Wang JJian
4Zhang YYubo
5Chang XXiaowei
6Jin DDong
7Lei PPeng
8Lu ZZhenhui
9Chen BBendonghttps://orcid.org/0000-0002-9636-847X

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124581682Cholangiocarcinoma.Lancet2014https://conductscience.org/library/papers/24581682PubMed
230251463Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.Hepatology2019https://conductscience.org/library/papers/30251463PubMed
323276796RLIP76 is overexpressed in human glioblastomas and is required for proliferation, tumorigenesis and suppression of apoptosis.Carcinogenesis2013https://conductscience.org/library/papers/23276796PubMed
432280242LncRNA FTX Contributes to the Progression of Colorectal Cancer Through Regulating miR-192-5p/EIF5A2 Axis.Onco Targets Ther2020https://conductscience.org/library/papers/32280242PubMed
528994423Cholangiocarcinoma - evolving concepts and therapeutic strategies.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/28994423PubMed
631180332MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p.Aging (Albany NY)2019https://conductscience.org/library/papers/31180332PubMed
730850362MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer.Cancer Genomics Proteomics2019https://conductscience.org/library/papers/30850362PubMed
828465351An HNF4α-microRNA-194/192 signaling axis maintains hepatic cell function.J Biol Chem2017https://conductscience.org/library/papers/28465351PubMed
924140396Pathogenesis, diagnosis, and management of cholangiocarcinoma.Gastroenterology2013https://conductscience.org/library/papers/24140396PubMed
1023948699Targeting MicroRNAs for personalized cancer therapy.Med Princ Pract2013https://conductscience.org/library/papers/23948699PubMed
1130653586Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma.PLoS One2019https://conductscience.org/library/papers/30653586PubMed
1224968698Genomic characterization of acute leukemias.Med Princ Pract2014https://conductscience.org/library/papers/24968698PubMed
1328598255The regulatory role of miRNAs on VDR in breast cancer.Transcription2017https://conductscience.org/library/papers/28598255PubMed
1427212195miRNA-223 inhibits epithelial-mesenchymal transition in gastric carcinoma cells via Sp1.Int J Oncol2016https://conductscience.org/library/papers/27212195PubMed
1533061591CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.Cancer Manag Res2020https://conductscience.org/library/papers/33061591PubMed
1626064276Study on the molecular regulatory mechanism of MicroRNA-195 in the invasion and metastasis of colorectal carcinoma.Int J Clin Exp Med2015https://conductscience.org/library/papers/26064276PubMed
1729749758The role of miR-92b in cholangiocarcinoma patients.Int J Biol Markers2018https://conductscience.org/library/papers/29749758PubMed
1812884914Role of MAP kinase in tumor progression and invasion.Cancer Metastasis Rev2003https://conductscience.org/library/papers/12884914PubMed
1929571988MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.Lung Cancer2018https://conductscience.org/library/papers/29571988PubMed
2030805558microRNA-1236-3p Regulates DDP Resistance in Lung Cancer Cells.Open Med (Wars)2018https://conductscience.org/library/papers/30805558PubMed

See all 43 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
41683945Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence.Int J Mol Sci2026https://conductscience.org/library/papers/41683945PubMed
40723336ERK1/2 Signaling in Intrahepatic Cholangiocarcinoma: From Preclinical Advances to Therapeutic Strategies.Biology (Basel)2025https://conductscience.org/library/papers/40723336PubMed
40087755Molecular mechanisms of miR-192 in cancer: a biomarker and therapeutic target.Cancer Cell Int2025https://conductscience.org/library/papers/40087755PubMed
38105269Overexpression of microRNA-205-5p promotes cholangiocarcinoma growth by reducing expression of homeodomain-interacting protein kinase 3.Sci Rep2023https://conductscience.org/library/papers/38105269PubMed
36053263Long non-coding RNA WAC antisense RNA 1 mediates hepatitis B virus replication <em>in vitro</em> by reinforcing miR-192-5p/ATG7-induced autophagy.Eur J Histochem2022https://conductscience.org/library/papers/36053263PubMed
35836925MiR-192-5p Alleviated Fibrosis and Inflammatory Responses of Tendon Cells by Targeting NFAT5.Comput Math Methods Med2022https://conductscience.org/library/papers/35836925PubMed
34953057MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.Thorac Cancer2022https://conductscience.org/library/papers/34953057PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DNTT1791PubTator's text mininghttps://conductscience.org/library/genes/1791NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33552829

GET https://conductscience.org/api/papers/v1/33552829/references?page=2